Professor Graham Cookson responds to President Donald Trump's Executive Order on drug prices published earlier this week.

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, ...

Dimitrios is an economist and his research interests lie in the fields of the economics of innovation and specifically on the economics of pharmaceutical markets and R&D. In addition, he is interested ...

Laura Vallejo-Torres is Associate Professor at the University of Las Palmas de Gran Canaria, Spain. She holds an MSc in Health Economics from the University of York and a Ph.D. in Health Economics ...

The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England. High Proportion of ...

Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence. Economic evaluations can ...

Immunisation programmes are foundational to public health. Organised by health authorities, they systematically deliver vaccines to susceptible populations to prevent the spread of infectious diseases ...

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...

OHE Graduate School actively supports and invests in the development of future health economists, underscoring our dedication to advancing evidence-based health policy. As part of our commitment to ...